Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...
In a deal that could top $1 billion, Merck & Co has teamed up with US biotech Janux Therapeutics to bring T-cell immunotherapies to cancer patients. The agreement sees San Diego-based Janux in ...
Merck & Co is enjoying blockbuster revenues as its cancer immunotherapy Keytruda is becoming standard of care in a range of cancers. But some of those revenues are helping British scientists ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback